7 ALS Headlines You Can’t Miss

3 – Eisai Withdraws Application for Ultra-High Dose of Mecobalamin, a B12 Form, as ALS Treatment

Vitamin B12 and ALS

Eisai announced it has withdrawn its new drug application for an ultra-high dose Mecobalamin as a treatment for amyotrophic lateral sclerosis (ALS) in Japan, and is reviewing its next steps in consultation with Japanese regulatory officials.

Read full here: http://bit.ly/1o6v4Oh

Leave a Comment

Your email address will not be published. Required fields are marked *